{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:06:26Z","timestamp":1791860786938,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05647-1","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:47:44Z","timestamp":1769150864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phosphorylated Tau Biomarkers in Alzheimer\u2019s Disease: From Early Detection to Clinical Potential\u2014A Comprehensive Review"],"prefix":"10.1007","volume":"63","author":[{"given":"Prasanna","family":"Karur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kaldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatin Srinivash","family":"Ramesh Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur S.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"5","key":"5647_CR1","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","volume":"20","author":"AsA","year":"2024","unstructured":"AsA (2024) 2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 20(5):3708\u20133821. https:\/\/doi.org\/10.1002\/alz.13809","journal-title":"Alzheimers Dement"},{"issue":"6","key":"5647_CR2","doi-asserted-by":"publisher","first-page":"e2513931","DOI":"10.1001\/jamanetworkopen.2025.13931","volume":"8","author":"S Mudrazija","year":"2025","unstructured":"Mudrazija S, Aranda MP, Gaskin DJ, Monroe S, Richard P (2025) Economic Burden of Alzheimer Disease and Related Dementias by Race and Ethnicity, 2020 to 2060. JAMA Netw Open 8(6):e2513931. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.13931","journal-title":"JAMA Netw Open"},{"key":"5647_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123001","volume":"355","author":"J Tran","year":"2024","unstructured":"Tran J, Parekh S, Rockcole J, Wilson D, Parmar MS (2024) Repurposing antidiabetic drugs for Alzheimer\u2019s disease: a review of preclinical and clinical evidence and overcoming challenges. Life Sci 355:123001. https:\/\/doi.org\/10.1016\/j.lfs.2024.123001","journal-title":"Life Sci"},{"issue":"8","key":"5647_CR4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.67037","volume":"16","author":"WS Roberts","year":"2024","unstructured":"Roberts WS, Price S, Wu M, Parmar MS (2024) Emerging gene therapies for Alzheimer\u2019s and Parkinson\u2019s diseases: an overview of clinical trials and promising candidates. Cureus 16(8):e67037. https:\/\/doi.org\/10.7759\/cureus.67037","journal-title":"Cureus"},{"key":"5647_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-05234-4","author":"S Patel","year":"2025","unstructured":"Patel S, Thornton A, Parmar MS (2025) Resveratrol\u2019s multifaceted potential in Alzheimer\u2019s disease: insights from preclinical and clinical evidence. Mol Neurobiol. https:\/\/doi.org\/10.1007\/s12035-025-05234-4","journal-title":"Mol Neurobiol"},{"key":"5647_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14333","author":"A Atri","year":"2024","unstructured":"Atri A, Dickerson BC, Clevenger C, Karlawish J, Knopman D, Lin PJ, Norman M, Onyike C, et al. (2024) Alzheimer\u2019s Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer\u2019s Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for primary care. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.14333","journal-title":"Alzheimers Dement"},{"issue":"6","key":"5647_CR7","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, et al. (2014) Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol 13(6):614\u2013629. https:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0","journal-title":"Lancet Neurol"},{"issue":"9","key":"5647_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18362","volume":"13","author":"AL Hobday","year":"2021","unstructured":"Hobday AL, Parmar MS (2021) The link between diabetes mellitus and tau hyperphosphorylation: implications for risk of Alzheimer\u2019s disease. Cureus 13(9):e18362. https:\/\/doi.org\/10.7759\/cureus.18362","journal-title":"Cureus"},{"key":"5647_CR9","doi-asserted-by":"publisher","unstructured":"Angelica Ortega, Brendan Chernicki, Ou G, Parmar MS (2024) From lab bench to hope: emerging gene therapies in clinical trials for Alzheimer\u2019s disease. https:\/\/doi.org\/10.1007\/s12035-024-04285-3","DOI":"10.1007\/s12035-024-04285-3"},{"issue":"1","key":"5647_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3233\/JAD-215699","volume":"87","author":"CK Kim","year":"2022","unstructured":"Kim CK, Lee YR, Ong L, Gold M, Kalali A, Sarkar J (2022) Alzheimer\u2019s disease: key insights from two decades of clinical trial failures. J Alzheimers Dis 87(1):83\u2013100. https:\/\/doi.org\/10.3233\/JAD-215699","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"5647_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1474-4422(16)30395-7","volume":"16","author":"The Lancet Neurology","year":"2017","unstructured":"The Lancet Neurology (2017) Solanezumab: too late in mild Alzheimer\u2019s disease? Lancet Neurol 16(2):97. https:\/\/doi.org\/10.1016\/S1474-4422(16)30395-7","journal-title":"Lancet Neurol"},{"issue":"4","key":"5647_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K (2014) Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6(4):37. https:\/\/doi.org\/10.1186\/alzrt269","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"5647_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, et al. (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement 7(4):367\u2013385. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2351","journal-title":"Alzheimers Dement"},{"key":"5647_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103836","volume":"76","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brum WS, Mathotaarachchi S, Therriault J, et al. (2022) Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease. EBioMedicine 76:103836. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103836","journal-title":"EBioMedicine"},{"key":"5647_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.695696","volume":"12","author":"YL Wang","year":"2021","unstructured":"Wang YL, Chen J, Du ZL, Weng H, Zhang Y, Li R, Jia Z, Sun M, et al. (2021) Plasma p-tau181 level predicts neurodegeneration and progression to Alzheimer\u2019s dementia: a longitudinal study. Front Neurol 12:695696. https:\/\/doi.org\/10.3389\/fneur.2021.695696","journal-title":"Front Neurol"},{"issue":"3","key":"5647_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez J, Karikari TK, Suarez-Calvet M, Troakes C, King A, Emersic A, Aarsland D, Hye A, et al. (2020) Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol 140(3):267\u2013278. https:\/\/doi.org\/10.1007\/s00401-020-02195-x","journal-title":"Acta Neuropathol"},{"key":"5647_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03622-w","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist S, Warmenhoven N, Anastasi F, Pilotto A, Janelidze S, Tideman P, Stomrud E, Mattsson-Carlgren N, et al. (2025) Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03622-w","journal-title":"Nat Med"},{"issue":"2","key":"5647_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14508","volume":"21","author":"NJ Ashton","year":"2025","unstructured":"Ashton NJ, Keshavan A, Brum WS, Andreasson U, Arslan B, Droescher M, Barghorn S, Vanbrabant J, et al. (2025) The Alzheimer\u2019s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau round robin study. Alzheimers Dement 21(2):e14508. https:\/\/doi.org\/10.1002\/alz.14508","journal-title":"Alzheimers Dement"},{"issue":"1","key":"5647_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54878-8","volume":"16","author":"AL Wojda\u0142a","year":"2025","unstructured":"Wojda\u0142a AL, Bellomo G, Gaetani L, Teunissen CE, Parnetti L, Chiasserini D (2025) Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer\u2019s disease biomarkers. Nat Commun 16(1):214. https:\/\/doi.org\/10.1038\/s41467-024-54878-8","journal-title":"Nat Commun"},{"issue":"1","key":"5647_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-024-00417-w","volume":"13","author":"LK Penny","year":"2024","unstructured":"Penny LK, Lofthouse R, Arastoo M, Porter A, Palliyil S, Harrington CR, Wischik CM (2024) Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer\u2019s disease. Transl Neurodegener 13(1):25. https:\/\/doi.org\/10.1186\/s40035-024-00417-w","journal-title":"Transl Neurodegener"},{"key":"5647_CR21","doi-asserted-by":"publisher","unstructured":"Chen X, Jiang M, Zhang L, Zhu J, Li A, He Z, Zhou X, Zhu Y, Zhang C, Wang C et al (2026) Association of plasma p-tau and p-tau\/A\u03b2 ratio with Alzheimer's pathology. J Prev Alzheimers Dis 100472. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100472","DOI":"10.1016\/j.tjpad.2025.100472"},{"issue":"1","key":"5647_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, Rodriguez-Baz I, Ferrer R, Carmona-Iragui M, Barroeta I, Illan-Gala I, et al. (2024) Diagnostic performance of plasma pTau(217), pTau(181), Abeta(1-42) and Abeta(1-40) in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res Ther 16(1):139. https:\/\/doi.org\/10.1186\/s13195-024-01513-9","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"5647_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, Langhough RE, Cody K, et al. (2024) Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol 81(3):255\u2013263. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319","journal-title":"JAMA Neurol"},{"issue":"6","key":"5647_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med 284(6):643\u2013663. https:\/\/doi.org\/10.1111\/joim.12816","journal-title":"J Intern Med"},{"issue":"12","key":"5647_CR25","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, Gonzalez-Ortiz F, et al. (2022) Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med 28(12):2555\u20132562. https:\/\/doi.org\/10.1038\/s41591-022-02074-w","journal-title":"Nat Med"},{"issue":"9","key":"5647_CR26","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mila-Aloma","year":"2022","unstructured":"Mila-Aloma M, Ashton NJ, Shekari M, Salvado G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, et al. (2022) Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer\u2019s disease. Nat Med 28(9):1797\u20131801. https:\/\/doi.org\/10.1038\/s41591-022-01925-w","journal-title":"Nat Med"},{"issue":"5","key":"5647_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, Snellman A, Scholl M, et al. (2021) Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol 141(5):709\u2013724. https:\/\/doi.org\/10.1007\/s00401-021-02275-6","journal-title":"Acta Neuropathol"},{"issue":"2","key":"5647_CR28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/brain\/awae346","volume":"148","author":"N Warmenhoven","year":"2025","unstructured":"Warmenhoven N, Salvad\u00f3 G, Janelidze S, Mattsson-Carlgren N, Bali D, Ordu\u00f1a Dolado A, Kolb H, Triana-Baltzer G, et al. (2025) A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain 148(2):416\u2013431. https:\/\/doi.org\/10.1093\/brain\/awae346","journal-title":"Brain"},{"issue":"5","key":"5647_CR29","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1002\/alz.13764","volume":"20","author":"MR Meyer","year":"2024","unstructured":"Meyer MR, Kirmess KM, Eastwood S, Wente-Roth TL, Irvin F, Holubasch MS, Venkatesh V, Fogelman I, et al. (2024) Clinical validation of the PrecivityAD2 blood test: a mass spectrometry\u2010based test with algorithm combining %p\u2010tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid. Alzheimers Dement 20(5):3179\u20133192. https:\/\/doi.org\/10.1002\/alz.13764","journal-title":"Alzheimers Dement"},{"issue":"11","key":"5647_CR30","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1002\/alz.13026","volume":"19","author":"J Therriault","year":"2023","unstructured":"Therriault J, Servaes S, Tissot C, Rahmouni N, Ashton NJ, Benedet AL, Karikari TK, Macedo AC, et al. (2023) Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement 19(11):4967\u20134977. https:\/\/doi.org\/10.1002\/alz.13026","journal-title":"Alzheimers Dement"},{"issue":"9","key":"5647_CR31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, Spina S, Allen IE, et al. (2021) Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 20(9):739\u2013752. https:\/\/doi.org\/10.1016\/S1474-4422(21)00214-3","journal-title":"Lancet Neurol"},{"key":"5647_CR32","doi-asserted-by":"publisher","unstructured":"Mielke MM, Aakre JA, Algeciras-Schimnich A, Proctor NK, Machulda MM, Eichenlaub U, Knopman DS, Vemuri P, et al. (2022) Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimers Dement 18(4):602\u2013611. https:\/\/doi.org\/10.1002\/alz.12415","DOI":"10.1002\/alz.12415"},{"issue":"17","key":"5647_CR33","doi-asserted-by":"publisher","first-page":"e1681","DOI":"10.1212\/WNL.0000000000012727","volume":"97","author":"A Leuzy","year":"2021","unstructured":"Leuzy A, Janelidze S, Mattsson-Carlgren N, Palmqvist S, Jacobs D, Cicognola C, Stomrud E, Vanmechelen E, et al. (2021) Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 assays. Neurology 97(17):e1681\u2013e1694. https:\/\/doi.org\/10.1212\/WNL.0000000000012727","journal-title":"Neurology"},{"issue":"5","key":"5647_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/alz.12236","volume":"17","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Emersic A, Vrillon A, Lantero-Rodriguez J, Ashton NJ, Kramberger MG, Dumurgier J, Hourregue C, et al. (2021) Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer\u2019s disease diagnosis. Alzheimers Dement 17(5):755\u2013767. https:\/\/doi.org\/10.1002\/alz.12236","journal-title":"Alzheimers Dement"},{"issue":"10","key":"5647_CR35","doi-asserted-by":"publisher","first-page":"e1009","DOI":"10.1212\/WNL.0000000000201647","volume":"100","author":"M Kurihara","year":"2023","unstructured":"Kurihara M, Komatsu H, Sengoku R, Shibukawa M, Morimoto S, Matsubara T, Arakawa A, Orita M, et al. (2023) CSF P-Tau181 and other biomarkers in patients with neuronal intranuclear inclusion disease. Neurology 100(10):e1009\u2013e1019. https:\/\/doi.org\/10.1212\/WNL.0000000000201647","journal-title":"Neurology"},{"issue":"1","key":"5647_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01709-9","volume":"11","author":"XN Shen","year":"2021","unstructured":"Shen XN, Huang YY, Chen SD, Guo Y, Tan L, Dong Q, Yu JT (2021) Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer\u2019s amyloid, tau and FDG PET status. Transl Psychiatry 11(1):585. https:\/\/doi.org\/10.1038\/s41398-021-01709-9","journal-title":"Transl Psychiatry"},{"issue":"1","key":"5647_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13195-021-00802-x","volume":"13","author":"C Tissot","year":"2021","unstructured":"Tissot C, A LB, Therriault J, Pascoal TA, Lussier FZ, Saha-Chaudhuri P, Chamoun M, Savard M, et al. (2021) Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer\u2019s disease. Alzheimers Res Ther 13(1):69. https:\/\/doi.org\/10.1186\/s13195-021-00802-x","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"5647_CR38","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, et al. (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19(5):422\u2013433. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5","journal-title":"Lancet Neurol"},{"issue":"3","key":"5647_CR39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y, et al. (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med 26(3):387\u2013397. https:\/\/doi.org\/10.1038\/s41591-020-0762-2","journal-title":"Nat Med"},{"issue":"8","key":"5647_CR40","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, Airey DC, Knopman DS, et al. (2018) Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement 14(8):989\u2013997. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.013","journal-title":"Alzheimers Dement"},{"issue":"2","key":"5647_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14609","volume":"21","author":"F Anastasi","year":"2025","unstructured":"Anastasi F, Fern\u00e1ndez-Lebrero A, Ashton NJ, Ortiz-Romero P, Torres-Torronteras J, Gonz\u00e1lez-Escalante A, Mil\u00e0-Alom\u00e0 M, Contador J, et al. (2025) A head-to-head comparison of plasma biomarkers to detect Alzheimer\u2019s disease in a memory clinic. Alzheimers Dement 21(2):e14609. https:\/\/doi.org\/10.1002\/alz.14609","journal-title":"Alzheimers Dement"},{"issue":"1","key":"5647_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, Proctor NK, Chai X, et al. (2020) Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun 11(1):1683. https:\/\/doi.org\/10.1038\/s41467-020-15436-0","journal-title":"Nat Commun"},{"issue":"3","key":"5647_CR43","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, et al. (2020) A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med 26(3):398\u2013407. https:\/\/doi.org\/10.1038\/s41591-020-0781-z","journal-title":"Nat Med"},{"issue":"12","key":"5647_CR44","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Su\u00e1rez-Calvet","year":"2020","unstructured":"Su\u00e1rez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodr\u00edguez J, Mil\u00e0-Alom\u00e0 M, Gispert JD, Salvad\u00f3 G, Minguillon C, et al. (2020) Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Mol Med 12(12):e12921. https:\/\/doi.org\/10.15252\/emmm.202012921","journal-title":"EMBO Mol Med"},{"issue":"1","key":"5647_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/14789450.2021.1886929","volume":"18","author":"N Campese","year":"2021","unstructured":"Campese N, Palermo G, Del Gamba C, Beatino MF, Galgani A, Belli E, Del Prete E, Della Vecchia A, et al. (2021) Progress regarding the context-of-use of tau as biomarker of Alzheimer\u2019s disease and other neurodegenerative diseases. Expert review of proteomics 18(1):27\u201348","journal-title":"Expert review of proteomics"},{"key":"5647_CR46","doi-asserted-by":"publisher","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, et al. (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","DOI":"10.1002\/alz.13859"},{"key":"5647_CR47","unstructured":"Diagnostics L (2025) LucentAD p-Tau 217. https:\/\/www.lucentdiagnostics.com\/lucentad-p-tau-217\/. Accessed Dec 2025"},{"issue":"11","key":"5647_CR48","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, Dage JL, Ferber K, et al. (2024) Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. Alzheimers Dement 20(11):8074\u20138096. https:\/\/doi.org\/10.1002\/alz.14315","journal-title":"Alzheimers Dement"},{"issue":"7","key":"5647_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70535","volume":"21","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist S, Whitson HE, Allen LA, Suarez-Calvet M, Galasko D, Karikari TK, Okrahvi HR, Paczynski M, et al. (2025) Alzheimer\u2019s Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings. Alzheimers Dement 21(7):e70535. https:\/\/doi.org\/10.1002\/alz.70535","journal-title":"Alzheimers Dement"},{"key":"5647_CR50","unstructured":"Smith T (2024) New blood tests for Alzheimer\u2019s may allow for earlier detection. UCHealth Today"},{"key":"5647_CR51","unstructured":"Labcorp (2024) Phosphorylated Tau 217 (pTau-217), Plasma. https:\/\/www.labcorp.com\/tests\/484390\/phosphorylated-tau-217-ptau-217-plasma"},{"key":"5647_CR52","unstructured":"Frey B (2023) Development of seed amplificafion assays as biomarkers for Alzheimer\u2019s & Parkinson\u2019s disease. Dissertation, Hannover, Tier\u00e4rztliche Hochschule Hannover"},{"issue":"3","key":"5647_CR53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jamaneurol.2018.4249","volume":"76","author":"JC Morris","year":"2019","unstructured":"Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, et al. (2019) Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol 76(3):264\u2013273. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4249","journal-title":"JAMA Neurol"},{"issue":"12","key":"5647_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.17363","volume":"2","author":"SL Garrett","year":"2019","unstructured":"Garrett SL, McDaniel D, Obideen M, Trammell AR, Shaw LM, Goldstein FC, Hajjar I (2019) Racial disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw Open 2(12):e1917363. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.17363","journal-title":"JAMA Netw Open"},{"issue":"3","key":"5647_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14367","volume":"21","author":"AJ Griswold","year":"2025","unstructured":"Griswold AJ, Rajabli F, Gu T, Arvizu J, Golightly CG, Whitehead PL, Hamilton-Nelson KL, Adams LD, et al. (2025) Generalizability of tau and amyloid plasma biomarkers in Alzheimer\u2019s disease cohorts of diverse genetic ancestries. Alzheimers Dement 21(3):e14367. https:\/\/doi.org\/10.1002\/alz.14367","journal-title":"Alzheimers Dement"},{"issue":"3","key":"5647_CR56","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/alz.13676","volume":"20","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Uhm H, Ip FC, Ouyang L, Lo RMN, Cheng EYL, Cao X, Tan CMC, et al. (2024) A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer\u2019s disease across ethnic groups. Alzheimers Dement 20(3):2000\u20132015. https:\/\/doi.org\/10.1002\/alz.13676","journal-title":"Alzheimers Dement"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05647-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05647-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05647-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:47:45Z","timestamp":1769150865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05647-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5647"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05647-1","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"No consent is needed, as the study did not involve human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"No consent is needed, as this manuscript contains no personal data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"To refine the final written draft of the article, the author(s) utilized artificial intelligence (AI) software, such as Gemini, to assist in identifying and correcting grammatical errors and enhancing the overall readability of the final draft. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"389"}}